Last reviewed · How we verify
Placebo to V920
V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection.
V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection. Used for HPV-related cervical intraepithelial neoplasia (CIN), HPV-related oropharyngeal or anogenital lesions.
At a glance
| Generic name | Placebo to V920 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Therapeutic vaccine |
| Target | Human papillomavirus (HPV) antigens |
| Modality | Biologic |
| Therapeutic area | Oncology / Immunology |
| Phase | Phase 3 |
Mechanism of action
V920 is an investigational HPV vaccine candidate in development by Merck Sharp & Dohme. As a therapeutic vaccine (rather than prophylactic), it is intended to generate cellular and humoral immune responses to target HPV-infected cells. The vaccine is being evaluated in Phase 3 trials for treatment of HPV-related diseases.
Approved indications
- HPV-related cervical intraepithelial neoplasia (CIN)
- HPV-related oropharyngeal or anogenital lesions
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola (PHASE2)
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) (PHASE1)
- Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) (PHASE1)
- Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) (PHASE1)
- Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to V920 CI brief — competitive landscape report
- Placebo to V920 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI